Corbus Pharmaceuticals (CRBP) AI Stock Analysis

• Market Cap: $83.79M
• Dividend Yield: N/A
• Average Volume (3M): 268.06K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.44
• Revenue Growth: N/A
• EPS Growth: 58.00%
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -4.70
• Shares Outstanding: 12,179,482
• 10 Day Avg. Volume: 206,166
• 30 Day Avg. Volume: 268,059
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $53.63
• Price Target Upside: 735.36% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

Corbus Pharmaceuticals is challenged by severe financial instability with no recent revenue and ongoing losses. The technical outlook is bearish, with the stock showing strong downward momentum. While a promising Phase 1 trial result offers hope, the immediate financial and technical concerns weigh heavily on the stock's overall score.

Positive Factors

Financial Performance

Corbus reported a net loss that was better than both the analyst's and consensus estimates, driven primarily by lower-than-expected R&D and SG&A expenses.

Regulatory Approval

The FDA granted Fast Track designation for CRB-701 in relapsed or refractory metastatic cervical cancer.

Negative Factors

Market Sentiment

The short interest in Corbus Pharmaceuticals is 23.2% of the float, indicating a significant portion of the market is betting against the stock.

Corbus Pharmaceuticals Business Overview & Revenue Model

Company Description

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

How the Company Makes Money

Corbus Pharmaceuticals primarily makes money through the development and commercialization of its drug candidates. The company's revenue model involves advancing its drug pipeline through clinical trials, obtaining regulatory approvals, and subsequently partnering with larger pharmaceutical companies for distribution and commercialization. Key revenue streams include milestone payments from strategic partnerships, licensing agreements, and potential sales of its proprietary drugs once approved. Corbus relies on collaborations with other pharmaceutical companies and research institutions to enhance its research capabilities and expedite the development of its therapeutic candidates, which is crucial for generating future revenue.

Corbus Pharmaceuticals Financial Statement Overview

Summary

Corbus Pharmaceuticals faces significant financial challenges, particularly in profitability with negative profit margins and cash flow generation issues. Despite improvements in stockholders' equity, high operating losses and reliance on external funding remain concerns.

Income Statement

Corbus Pharmaceuticals' income statement reflects significant challenges in profitability. The TTM (Trailing-Twelve-Months) data shows a gross profit margin of 63%, which is positive. However, both the net profit margin and EBIT margin are highly negative, indicating substantial losses. Revenue growth is not applicable as previous periods reported zero revenue. The company needs to address its high operating losses to improve its financial health.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, primarily driven by negative equity in previous periods. Current data shows improved equity, but the leverage remains a concern. The equity ratio is robust due to a significant increase in stockholders' equity. Although the company has improved its equity position recently, the high historical leverage poses risks to financial stability.

Cash Flow

Cash flow analysis reveals a challenging scenario for Corbus Pharmaceuticals. The company has consistently negative free cash flow, and the operating cash flow to net income ratio is unfavorable, indicating cash flow issues. While there was a significant financing cash flow in the TTM period, reliance on external funding is not sustainable. The company must improve operational efficiency to generate positive cash flows.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.35M	0.00	0.00	881.71K	3.94M	36.14M
	Gross Profit
850.12K	-31.17M	-1.49M	-757.53K	3.84M	36.05M
	EBIT
-46.22M	-45.08M	-39.84M	-55.99M	-122.81M	-77.10M
	EBITDA
-41.82M	-44.44M	-38.73M	-54.97M	-121.69M	-76.37M
	Net Income Common Stockholders
-38.70M	-44.60M	-55.83M	-45.55M	-111.30M	-69.15M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
41.75M	20.91M	59.20M	97.65M	85.43M	31.75M
	Total Assets
46.99M	28.27M	66.31M	107.73M	102.29M	49.14M
	Total Debt
394.31K	20.88M	25.09M	26.59M	26.84M	9.45M
	Net Debt
-41.35M	7.16M	8.09M	1.58M	-58.60M	-22.30M
	Total Liabilities
19.47M	35.18M	33.32M	38.62M	57.02M	42.98M
	Stockholders Equity
27.52M	-6.90M	32.99M	69.11M	45.27M	6.16M
Cash Flow		Free Cash Flow
-36.86M	-36.10M	-37.56M	-48.24M	-100.17M	-48.46M
	Operating Cash Flow
-36.86M	-36.10M	-37.54M	-48.18M	-99.69M	-45.72M
	Investing Cash Flow
-119.65M	35.64M	30.07M	-73.42M	-484.49K	-2.74M
	Financing Cash Flow
164.69M	-2.82M	-533.62K	60.82M	154.87M	38.46M

Corbus Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 6.42 is below the 20-day moving average (MA) of 7.46, below the 50-day MA of 9.62, and below the 200-day MA of 29.47, indicating a bearish trend. The MACD of -0.91 indicates Negative momentum. The RSI at 28.73 is Positive, neither overbought nor oversold. The STOCH value of 18.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.

Corbus Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADMA	71 Outperform	$4.10B	22.72	81.65%	―	63.39%	―
KNSA	66 Neutral	$1.57B	―	-9.85%	―	56.60%	-403.56%
ANAB	59 Neutral	$537.90M	―	-182.71%	―	432.03%	14.41%
Sector *	49 Neutral	$6.84B	0.05	-53.14%	2.48%	24.49%	-3.26%
AKBA	46 Neutral	$421.09M	―	91.25%	―	-12.26%	32.86%
CRBP	32 Underperform	$83.79M	―	-51.32%	―	―	58.00%

Corbus Pharmaceuticals Corporate Events

Corbus Pharmaceuticals Reports Q4 2024 Financial Results

Corbus Pharmaceuticals reported its Q4 and 2024 financial results, highlighting significant progress in its oncology and obesity programs. The company announced encouraging Phase 1 results for CRB-701 in Western studies, with the FDA granting Fast Track designation for its use in metastatic cervical cancer. The company also plans to start a study for CRB-913 in March 2025. Financially, Corbus reported a net loss of $9.5 million for Q4 2024, with $149 million in cash and investments, expected to fund operations through Q3 2027.

Corbus Pharmaceuticals Reports Promising Phase 1 Trial Results

On February 14, 2025, Corbus Pharmaceuticals announced data from a Phase 1 clinical trial for CRB-701, presented at the ASCO GU Symposium. The trial in the US and UK showed promising safety and efficacy, with no dose-limiting toxicities and encouraging responses in several tumor types, including a first-time exploration in head and neck squamous cell carcinoma. This positions Corbus strongly within the oncology field, potentially impacting stakeholders positively.